Inventor

C. Frank Bennett

Inventor

Carlsbad, CA, US

Overview

1996–2020

Patent span

Chemistry

Primary field (CPC C)

Patents· 206 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary

C12NMicroorganisms or enzymes29%

A61KPreparations for medical, dental or toiletry purposes21%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%

Y02PClimate change mitigation technologies in the production or processing of goods10%

C07HSugars8%

C12YEnzymes5%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%

C07KPeptides4%

C07JSteroids1%

C07BGeneral methods of organic chemistry1%

PatentTitleYear

10,851,371Modulation of SMN expression2020 10,837,016Modulation of huntingtin expression2020 10,738,307Compositions and their uses directed to huntingtin2020 10,619,158Modulation of huntingtin expression2020 10,584,336Oligomeric compounds and compositions for use in modulation of small non-coding RNAs2020 10,577,604Methods for monitoring C9ORF72 expression2020 10,533,178Methods for modulating Ataxin 2 expression2020 10,526,604Modulation of nuclear-retained RNA2020 10,344,282Compositions and methods for modulation of IKBKAP splicing2019 10,301,627Targeting microRNAs for the treatment of liver cancer2019 10,273,474Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome2019 RE047320Modulation of CD40 expression2019 10,202,603Modulation of huntingtin expression2019 10,093,926Oligomeric compounds and compositions for use in modulation of small non-coding RNAs2018 10,072,265Oligomeric compounds and compositions for use in modulation of small non-coding RNAs2018 10,006,027Methods for modulating Ataxin 2 expression2018 9,963,699Methods for modulating C9ORF72 expression2018 9,926,559'Compositions and methods for modulation of SMN2 splicing in a subject'2018 9,856,473'Compositions and methods for modulation of LMNA expression'2018 9,845,470Targeting microRNAS for the treatment of liver cancer2017 9,845,467Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals2017 9,765,338'Modulation of dystrophia myotonica-protein kinase (DMPK) expression'2017 9,752,146'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2017 9,717,750'Compositions and methods for modulation of SMN2 splicing in a subject'2017 9,688,987'Antisense oligonucleotides directed against connective tissue growth factor and uses thereof'2017 9,683,236'Modulation of huntingtin expression'2017 9,663,787'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2017 9,605,259'Compounds and methods for modulating protein expression'2017 9,546,368'Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression'2017 9,528,108'Oligomeric compounds and compositions for use in modulation of small non-coding RNAS'2016 9,518,259'Compounds and methods for modulating interaction between proteins and target nucleic acids'2016 9,506,062'Targeting microRNAs for the treatment of liver cancer'2016 9,476,051'Antisense modulation of superoxide dismutase 1, soluble expression'2016 9,447,413'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2016 9,447,412'Oligomeric compounds and compositions for use in modulation of small non-coding RNAS'2016 9,353,371'Antisense compounds targeting genes associated with usher syndrome'2016 9,273,315'Modulation of huntingtin expression'2016 9,267,138'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2016 9,157,081'Chimeric oligomeric compounds for modulation of splicing'2015 9,150,857'Targeting microRNAs for the treatment of liver cancer'2015 9,139,832'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2015 9,096,851'Antisense oligonucleotides directed against connective tissue growth factor and uses thereof'2015 9,057,066'Compositions and their uses directed to huntingtin'2015 9,006,198'Selective reduction of allelic variants'2015 8,999,951'Compounds and methods for improving cellular uptake of oligomeric compounds'2015 8,993,529'Antisense modulation of superoxide dismutase 1, soluble expression'2015 8,980,853'Compositions and methods for modulation of SMN2 splicing in a subject'2015 8,957,040'Selective reduction of allelic variants'2015 8,946,172'Method for reducing scarring during wound healing using antisense compounds directed to CTGF'2015 8,946,179'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2015 8,921,331'Methods for slowing familial ALS disease progression'2014 8,916,531'Modulation of CD40 expression'2014 8,906,873'Modulation of huntingtin expression'2014 8,859,521'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2014 8,809,294'Method of inhibiting miR-33 using a modified oligonucleotide'2014 8,791,088'Compositions and methods for modulation of LMNA expression'2014 8,772,260'Methods for inhibiting expression of connective tissue growth factor'2014 8,765,701'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2014 8,697,663'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2014 8,680,067'Targeting microRNAs for the treatment of liver cancer'2014 8,669,102'Modulation of prion expression'2014 8,637,478'Compounds and methods for modulating protein expression'2014 8,546,350'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2013 8,501,703'Chimeric oligomeric compounds for modulation of splicing'2013 8,318,496'Compounds and methods for improving cellular uptake of oligomeric compounds'2012 8,258,109'Compositions and methods for modulation of LMNA expression'2012 8,252,762'Antisense oligonucleotides directed against connective tissue growth factor and uses thereof'2012 8,211,867'Targeting microRNAs for the treatment of liver cancer'2012 8,198,253'Compositions and their uses directed to HBXIP'2012 8,178,506'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2012 8,153,602'Composition and methods for the pulmonary delivery of nucleic acids'2012 8,133,876'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2012 8,110,558'Oligomeric compounds and compositions for use in modulation of small non-coding RNAS'2012 8,106,025'Method for inhibiting the activity of mir-155'2012 8,076,306'Compositions and their uses directed to hepcidin'2011 7,960,355'Compositions and methods for the modulation of the expression of B7 protein'2011 7,902,163'Antisense modulation of superoxide dismutase 1, soluble expression'2011 7,897,582'Oligonucleotide compositions and methods for the modulation of the expression of B7 protein'2011 7,884,086'Conjugates for use in hepatocyte free uptake assays'2011 7,745,609'Antisense modulation of CD40 expression'2010 7,700,574'Modulation of RANKL expression'2010 7,683,036'Oligomeric compounds and compositions for use in modulation of small non-coding RNAs'2010 7,678,895'Antisense modulation of superoxide dismutase 1, soluble expression'2010 7,622,455'Methods for slowing familial ALS disease progression'2009 7,339,051'Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)'2008 7,288,530'Antisense modulation of survivin expression'2007 7,235,650'Derivatized oligonucleotides having improved uptake and other properties'2007 7,235,653'Oligonucleotide compositions and methods for the modulation of the expression of B7 protein'2007 7,148,204'Antisense modulation of bcl-x expression'2006 7,132,530'Antisense modulation of superoxide dismutase 1, soluble expression'2006 7,125,975'Derivatized oligonucleotides having improved uptake and other properties'2006 7,122,649'Derivatized oligonucleotides having improved uptake and other properties'2006 7,115,580'Antisense modulation of B7 protein expression'2006 7,067,497'Modulation of telomere length by oligonucleotides having a G-core sequence'2006 6,919,439'Derivatized oligonucleotides having improved uptake and other properties'2005 6,900,306'Antisense modulation of CoREST expression'2005 6,870,046'Antisense modulation of interferon gamma receptor 2 expression'2005 6,849,612'Oligonucleotide modulation of cell adhesion'2005 6,838,283'Antisense modulation of survivin expression'2005 6,831,166'Derivatized oligonucleotides having improved uptake and other properties'2004 6,753,423'Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals'2004 6,746,868'Chemical modification of DNA using peptide nucleic acid conjugates'2004 6,734,017'Antisense modulation of vascular endothelial growth factor receptor-2 expression'2004 6,713,621'Chimeric oligonucleotides for modulating gene expression'2004 6,710,174'Antisense inhibition of vascular endothelial growth factor receptor-1 expression'2004 6,692,959'Antisense modulation of IL-1 receptor-associated kinase-4 expression'2004 6,692,960'Antisense modulation of sphingosine-1-phosphate lyase expression'2004 6,656,732'Antisense inhibition of src-c expression'2003 6,656,688'Antisense modulation of NF-kappa-B p65 subunit expression'2003 6,632,667'Modulation of L-selectin shedding via inhibition of tumor necrosis factor- converting enzyme (TACE)'2003 6,613,567'Antisense inhibition of Her-2 expression'2003 6,586,245'Antisense modulation of CD40 ligand expression'2003 6,537,973'Oligonucleotide inhibition of protein kinase C'2003 6,492,172'Antisense modulation of GU protein expression'2002 6,440,739'Antisense modulation of glioma-associated oncogene-2 expression'2002 6,426,220'Antisense modulation of calreticulin expression'2002 6,410,324'Antisense modulation of tumor necrosis factor receptor 2 expression'2002 6,410,325'Antisense modulation of phospholipase A2, group VI (Ca2-independent) expression'2002 6,399,376'Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions'2002 6,395,492'Derivatized oligonucleotides having improved uptake and other properties'2002 6,387,699'Antisense inhibition of A20 expression'2002 6,383,809'Antisense inhibition of cytohesin-1 expression'2002 6,372,433'Antisense modulation of inhibitor of DNA binding-1 expression'2002 6,372,492'Antisense modulation of talin expression'2002 6,365,354'Antisense modulation of lysophospholipase I expression'2002 6,355,482'Antisense inhibition of integrin beta 4 binding protein expression'2002 6,355,483'Antisenses inhibition of SRC-2 expression'2002 6,339,066'Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate I, II, , , , and isoforms of human protein kinase C'2002 6,335,194'Antisense modulation of survivin expression'2002 6,329,203'Antisense modulation of glioma-associated oncogene-1 expression'2001 6,319,906'Oligonucleotide compositions and methods for the modulation of the expression of B7 protein'2001 6,300,491'Oligonucleotide inhibition of cell adhesion'2001 6,294,382'Antisense modulation of SRC-1 expression'2001 6,277,640'Antisense modulation of Her-3 expression'2001 6,271,029'Antisense inhibition of cytohesin-2 expression'2001 6,265,216'Antisense modulation of cot oncogene expression'2001 6,258,790'Antisense modulation of integrin .alpha.4 expression'2001 6,255,111'Antisense modulation of Her-4 expression'2001 6,228,642'Antisense oligonucleotide modulation of tumor necrosis factor-(.alpha.) (TNF-.alpha.) expression'2001 6,225,293'Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations'2001 6,214,986'Antisense modulation of bcl-x expression'2001 6,210,892'Alteration of cellular behavior by antisense modulation of mRNA processing'2001 6,200,807'Antisense inhibition of SHP-2 expression'2001 6,197,584'Antisense modulation of CD40 expression'2001 6,190,869'Antisense inhibition of protein kinase C-theta expression'2001 6,187,585'Oligonucleotide inhibition of epidermal growth factor receptor expression'2001 6,180,403'Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression'2001 6,177,273'Antisense modulation of integrin-linked kinase expression'2001 6,172,216'Antisense modulation of BCL-X expression'2001 6,169,079'Oligonucleotide inhibition of cell adhesion'2001 6,165,786'Antisense modulation of nucleolin expression'2000 6,165,720'Chemical modification of DNA using peptide nucleic acid conjugates'2000 6,165,788'Antisense modulation of Survivin expression'2000 6,156,571'Antisense inhibition of SRC-3 expression'2000 6,153,737'Derivatized oligonucleotides having improved uptake and other properties'2000 6,150,162'Antisense modulation of CD44 expression'2000 6,140,126'Antisense modulation of Y-box binding protein 1 expression'2000 6,121,047'Antisense modulation of SHP-1 expression'2000 6,117,847'Oligonucleotides for enhanced modulation of protein kinase C expression'2000 6,111,094'Enhanced antisense modulation of ICAM-1'2000 6,107,092'Antisense modulation of SRA expression'2000 6,096,722'Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases'2000 6,093,811'Oligonucleotide modulation of cell adhesion'2000 6,087,173'Antisense modulation of X-linked inhibitor of apoptosis expression'2000 6,080,580'Antisense oligonucleotide modulation of tumor necrosis factor-.alpha. (TNF-.alpha.) expression'2000 6,077,709'Antisense modulation of Survivin expression'2000 6,077,833'Oligonucleotide compositions and methods for the modulation of the expression of B7 protein'2000 6,069,008'Antisense modulation of NF-kappa-B p65 subunit expression'2000 6,066,500'Antisense modulation of Beta catenin expression'2000 6,037,176'Antisense inhibition of integrin beta 3 expression'2000 6,025,198'Antisense modulation of Ship-2 expression'2000 6,020,198'Antisense modulation of RIP-1 expression'2000 6,015,894'Oligonucleotide modulation of cell adhesion'2000 6,015,892'Oligonucleotide modulation of protein kinase C'2000 6,008,344'Antisense modulation of phospholipase A2 group IV expression'1999 6,004,814'Antisense modulation of CD71 expression'1999 6,001,651'Antisense modulation of LFA-3'1999 6,001,992'Antisense modulation of novel anti-apoptotic bcl-2-related proteins'1999 5,998,148'Antisense modulation of microtubule-associated protein 4 expression'1999 5,985,663'Antisense inhibition of interleukin-15 expression'1999 5,968,826'Antisense inhibition of integrin .alpha.4 expression'1999 5,968,748'Antisense oligonucleotide modulation of human HER-2 expression'1999 5,958,772'Antisense inhibition of cellular inhibitor of apoptosis-1 expression'1999 5,959,096'Antisense oligonucleotides against human protein kinase C'1999 5,958,771'Antisense modulation of cellular inhibitor of Apoptosis-2 expression'1999 5,955,443'Antisense modulation of PECAM-1'1999 5,952,490'Oligonucleotides having a conserved G4 core sequence'1999 5,922,686'Oligonucleotide modulation of protein kinase C'1999 5,916,807'Antisense oligonucleotides against human protein kinase C'1999 5,914,269'Oligonucleotide inhibition of epidermal growth factor receptor expression'1999 5,885,970'Antisense oligonucleotides against human protein kinase C'1999 5,883,082'Compositions and methods for preventing and treating allograft rejection'1999 5,882,927'Oligonucleotide inhibition of protein kinase C'1999 5,856,099'Antisense compositions and methods for modulating type I interleukin-1 receptor expression'1999 5,843,738'Oligonucleotide modulation of cell adhesion'1998 5,814,619'Oligonucleotide inhibition of P120'1998 5,807,838'Oligonucleotide modulation of multidrug resistance-associated protein'1998 5,801,154'Antisense oligonucleotide modulation of multidrug resistance-associated protein'1998 5,789,573'Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2'1998 5,744,460'Combination for treatment of proliferative diseases'1998 5,703,054'Oligonucleotide modulation of protein kinase C'1997 5,656,743'Oligonucleotide modulation of cell growth'1997 5,591,623'Oligonucleotide modulation of cell adhesion'1997 5,530,114'Oligonucleotide modulation of arachidonic acid metabolism'1996 5,514,788'Oligonucleotide modulation of cell adhesion'1996 5,510,239'Oligonucleotide modulation of multidrug resistance-associated protein'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2019Patents assigned to ISIS PHARMACEUTICALS INC (154)· patent assignee history

1996–2020Based in Carlsbad, CA, US· patent location history

2010–2020Patents assigned to REGULUS THERAPEUTICS INC (27)· patent assignee history

2011–2016Patents assigned to BENNETT C FRANK (32)· patent assignee history

2012–2015Patents assigned to FREIER SUSAN M (17)· patent assignee history

2016–2020Patents assigned to IONIS PHARMACEUTICALS INC (23)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ISIS PHARMACEUTICALS INC	154	1996–2019
BENNETT C FRANKself	32	2011–2016
REGULUS THERAPEUTICS INC	27	2010–2020
IONIS PHARMACEUTICALS INC	23	2016–2020
FREIER SUSAN M	17	2012–2015

Locations

Location	Patents	Span
Carlsbad, California, US	206	1996–2020